Merrimack Pharmaceuticals (MACK) Earns Coverage Optimism Rating of 0.02

News stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 48.0154908756654 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

NASDAQ:MACK traded down $0.65 on Thursday, reaching $9.02. The company’s stock had a trading volume of 241,000 shares, compared to its average volume of 141,867. Merrimack Pharmaceuticals has a 12-month low of $7.36 and a 12-month high of $15.40. The company has a market capitalization of $118.62 million, a P/E ratio of -1.59 and a beta of 1.80.

Merrimack Pharmaceuticals (NASDAQ:MACK) last posted its earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.27) by $0.38. equities analysts expect that Merrimack Pharmaceuticals will post -4.66 EPS for the current year.

MACK has been the topic of a number of recent research reports. Robert W. Baird reissued a “hold” rating and set a $12.00 price objective on shares of Merrimack Pharmaceuticals in a research note on Thursday, March 15th. Zacks Investment Research lowered Merrimack Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 15th.

Merrimack Pharmaceuticals Company Profile

Merrimack Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply